261 related articles for article (PubMed ID: 32171354)
1. Facilitating equitable prevention and management of gout for Māori in Northland, New Zealand, through a collaborative primary care approach.
Lawrence A; Scott S; Saparelli F; Greville G; Miller A; Taylor A; Gow P
J Prim Health Care; 2019 Jul; 11(2):117-127. PubMed ID: 32171354
[TBL] [Abstract][Full Text] [Related]
2. Improving gout education from patients' perspectives: a focus group study of Māori and Pākehā people with gout.
Rolston CJ; Conner TS; Stamp LK; Neha T; Pitama S; Fanning N; Janes R; Judd A; Hudson B; Hegarty RM; Treharne GJ
J Prim Health Care; 2018 Oct; 10(3):194-200. PubMed ID: 31039932
[TBL] [Abstract][Full Text] [Related]
3. Design and implementation of a Pacific intervention to increase uptake of urate-lowering therapy for gout: a study protocol.
Ofanoa M; Ofanoa SM; Heather M; Tu'akoi S; Lutui H; Dalbeth N; Grey C; van der Werf B; Goodyear-Smith F
Int J Equity Health; 2021 Dec; 20(1):262. PubMed ID: 34949187
[TBL] [Abstract][Full Text] [Related]
4. The experience and impact of gout in Māori and Pacific people: a prospective observational study.
Dalbeth N; House ME; Horne A; Te Karu L; Petrie KJ; McQueen FM; Taylor WJ
Clin Rheumatol; 2013 Feb; 32(2):247-51. PubMed ID: 23114632
[TBL] [Abstract][Full Text] [Related]
5. Maori experiences and perceptions of gout and its treatment: a kaupapa Maori qualitative study.
Te Karu L; Bryant L; Elley CR
J Prim Health Care; 2013 Sep; 5(3):214-22. PubMed ID: 23998172
[TBL] [Abstract][Full Text] [Related]
6. The inequity of access to health: a case study of patients with gout in one general practice.
Karu LT; Harwood M; Arroll B; Bryant L; Kenealy T
N Z Med J; 2021 Oct; 134(1543):51-58. PubMed ID: 34695076
[TBL] [Abstract][Full Text] [Related]
7. Variation in gout care in Aotearoa New Zealand: a national analysis of quality markers.
Jackson G; Dalbeth N; Te Karu L; Winnard D; Gow P; Gerard C; Minko N
N Z Med J; 2014 Oct; 127(1404):37-47. PubMed ID: 25331310
[TBL] [Abstract][Full Text] [Related]
8. Interventions designed to improve uptake of allopurinol for gout treatment in Aotearoa New Zealand: a scoping review.
Ofanoa S; Ofanoa M; Tu'akoi S; Lutui H; Heather M; Jansen RM; Dalbeth N; Grey C; Goodyear-Smith F
J Prim Health Care; 2023 Mar; 15(1):48-58. PubMed ID: 37000552
[TBL] [Abstract][Full Text] [Related]
9. Adherence and persistence to urate-lowering therapies in the Irish setting.
McGowan B; Bennett K; Silke C; Whelan B
Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
[TBL] [Abstract][Full Text] [Related]
10. Allopurinol use in a New Zealand population: prevalence and adherence.
Horsburgh S; Norris P; Becket G; Arroll B; Crampton P; Cumming J; Keown S; Herbison P
Rheumatol Int; 2014 Jul; 34(7):963-70. PubMed ID: 24390636
[TBL] [Abstract][Full Text] [Related]
11. National prevalence of gout derived from administrative health data in Aotearoa New Zealand.
Winnard D; Wright C; Taylor WJ; Jackson G; Te Karu L; Gow PJ; Arroll B; Thornley S; Gribben B; Dalbeth N
Rheumatology (Oxford); 2012 May; 51(5):901-9. PubMed ID: 22253023
[TBL] [Abstract][Full Text] [Related]
12. Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study.
Yeo E; Palmer SC; Chapman PT; Frampton C; Stamp LK
Intern Med J; 2019 Jul; 49(7):838-842. PubMed ID: 30426652
[TBL] [Abstract][Full Text] [Related]
13. An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population.
Robinson PC; Taylor WJ; Dalbeth N
J Rheumatol; 2015 Sep; 42(9):1702-7. PubMed ID: 26233513
[TBL] [Abstract][Full Text] [Related]
14. Regular pre-admission urate-lowering therapy and serum urate testing are associated with a shorter hospital length of stay in people with gout: A nation-wide population-based cohort study.
Jatuworapruk K; Grainger R; Dalbeth N; Taylor WJ
Int J Rheum Dis; 2022 Feb; 25(2):154-162. PubMed ID: 34796661
[TBL] [Abstract][Full Text] [Related]
15. Hyperuricaemia and gout in New Zealand rural and urban Māori and non-Māori communities.
Stamp LK; Wells JE; Pitama S; Faatoese A; Doughty RN; Whalley G; Richards AM; Cameron VA
Intern Med J; 2013 Jun; 43(6):678-84. PubMed ID: 23279108
[TBL] [Abstract][Full Text] [Related]
16. The challenges of managing gout in primary care: Results of a best-practice audit.
Stamp LK; Chapman P; Hudson B; Frampton C; Hamilton G; Judd A
Aust J Gen Pract; 2019 Sep; 48(9):631-637. PubMed ID: 31476837
[TBL] [Abstract][Full Text] [Related]
17. The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand.
Stamp LK; Haslett J; Frampton C; White D; Gardner D; Stebbings S; Taylor G; Grainger R; Kumar R; Kumar S; Kain T; Porter D; Corkill M; Cathro A; Metcalfe S; Wyeth J; Dalbeth N
Intern Med J; 2016 Sep; 46(9):1075-80. PubMed ID: 27391386
[TBL] [Abstract][Full Text] [Related]
18. Does starting allopurinol prolong acute treated gout? A randomized clinical trial.
Hill EM; Sky K; Sit M; Collamer A; Higgs J
J Clin Rheumatol; 2015 Apr; 21(3):120-5. PubMed ID: 25807090
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) Study.
Coburn BW; Cheetham TC; Rashid N; Chang JM; Levy GD; Kerimian A; Low KJ; Redden DT; Bridges SL; Saag KG; Curtis JR; Mikuls TR
Contemp Clin Trials; 2016 Sep; 50():106-15. PubMed ID: 27449546
[TBL] [Abstract][Full Text] [Related]
20. Māori and Pacific peoples' experiences of a Māori-led diabetes programme.
Tane T; Selak V; Hawkins K; Lata V; Murray J; Nicholls D; Peihopa A; Rice N; Harwood M
N Z Med J; 2021 Oct; 134(1543):79-89. PubMed ID: 34695079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
